Sanaa Kamal, M.D., Ph.D.
Sanaa M. Kamal, M.D., Ph.D., is currently a professor of medicine at the Department of Gastroenterology and Liver Disease Center, Ain Shams School of Medicine, Cairo, Egypt. She has obtained her M.B, Bch., M.Sc. and M.D. in medicine from Ain Shams University, Cairo, Egypt. She obtained her Ph.D. from the University of Freiburg, Germany, in 1997. She received her postdoctoral training in hepatology and immunology from the Albert-Ludwig Uni-klinik, Freiburg, Germany, sponsored by the prestigious Alexander von Humboldt Grant, Jenner Research Institute, Oxford, UK, and the National Institutes of Health, Bethesda, USA. Here, she studied the characteristics of hepatitis C and Schistosoma mansoni coinfection. This yielded to the establishment of a unique model for viral/parasitic coinfection and a model for accelerated liver fibrosis presented in publication in LIVER, Journal of Hepatology and Journal of Infectious Diseases.
From 2000 to 2001, Dr. Kamal studied the correlates d and impact of HCV-immune responses on the outcome of acute hepatitis C and the progression of liver disease in chronic hepatitis C, sponsored by Fulbright Senior Scholar Research Award and a grant from the International Society of Infectious Diseases. This research was published in top tier journals, including Gastroenterology, Hepatology, Journal of Infectious Diseases, GUT, Journal of Virology, and Journal of Hepatology.
Dr. Kamal is also a visiting professor at Harvard Medical School and is the director of a Fulbright US/Egyptian collaborative program. She is a principle investigator on several NIH, NAID, European, and Egyptian research grants. She is an associate editor for LIVER International and a member in the editorial board of World Journal of Gastroenterology and a reviewer for more than 15 medical journals. She has written several editorials on hepatitis C, HCV-immune responses and viral parasitic interactions, and she is also heading a successful liver transplantation team in Cairo, Egypt. Dr. Kamal is also a member of the continuous medical education committee in Egypt, and supervises Egyptian Infection Control activities.
Naglaa H. Shoukry, B. Pharm., Ph.D., obtained her pharmacy degree from Cairo University (Cairo, Egypt) in 1991 and her Ph.D. in immunology from McGill University (Montreal, Canada) in 2000. During her postdoctoral training at Columbus Children's Research Institute (2000-2004), she demonstrated the essential role of CD4+ and CD8+ T cells in controlling HCV infection in the chimpanzee model. She is the lead author on several publications and review articles in top tier journals, including Annual Reviews, Journal of Experimental Medicine, and Science, and is the recipient of numerous awards from the American Liver Foundation, Canadian Institutes of Heath Research (CIHR) and Fonds de la recherche en santé du Québec (FRSQ).
In January 2005, Dr. Shoukry joined the University of Montreal as an assistant professor at the Department of Medicine. Her laboratory is located within the hepatology axis of the CHUM Research Centre at Saint Luc Hospital, a new, state-of-the-art research center dedicated to the study of hepatitis C. Her research is funded by CIHR, FRSQ and the Dana Foundation, and focuses on understanding the immune response and host-virus interactions during HCV infection. She is a Chercheur boursier junior 1 of the FRSQ, a mentor in the National Canadian Research Training Program on Hepatitis C (NCRTP-HepC), and a member of the INSERM (Unit 743) for research on immunovirology in Montreal.
Salim Khakoo, M.D., MRCP, is currently a Wellcome Trust senior fellow in Clinical Science and Professor of Hepatology at Imperial College, London. He was previously at Southampton University and Southampton General Hospital; he trained in hepatology at The Royal Free Hospital in London and subsequently as a post-doctoral fellow at Stanford University, USA. He combines his clinical interest in hepatology with a basic scientific interest in immunology, and now has an active research program studying the immunology of hepatitis C virus infection. This program encompasses cellular immunology and molecular genetics in order to give a wide perspective on the problem.